Shots:
- The EC has approved Capvaxive for active immunization against invasive disease & pneumonia caused by S. pneumoniae in adults (≥18yrs.) in 30 EEA states
- Approval was backed by P-III (STRIDE-3) data, assessing Capvaxive vs PCV20 in pneumococcal vaccine-naïve adults (≥18yrs.), plus data from various P-III trials (STRIDE-4, STRIDE-5, STRIDE-6, STRIDE-7, & STRIDE-10) assessing it in both vaccine-naïve & vaccinated adults
- STRIDE trials showed Capvaxive was non-inferior/superior to PCV20, PPSV23, & PCV15 by OPA GMTs, with strong immune responses for all serotypes. It also maintained efficacy in HIV pts (STRIDE-7), with QIV (STRIDE-5), & in previously vaccinated subjects (STRIDE-6 & 7)
Ref: Merck | Image: Merck
Related News:- Merck Partners with Jiangsu Hengrui Pharmaceuticals for HRS-5346, Expanding its Cardio-Metabolic Portfolio
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
